By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Quark Pharmaceuticals Inc. 

6501 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-402-4020 Fax: 510-402-4021


Company News
Quark Pharmaceuticals Inc. Reports Positive Results From A Phase II Study To Evaluate The Efficacy And Safety Of QPI-1002 For The Prevention Of Acute Kidney Injury (AKI) In Subjects At High Risk Of AKI Following Cardiac Surgery 7/27/2017 6:32:58 AM
Quark Pharmaceuticals Inc. Launches To Promote NAION Study 10/14/2016 11:17:12 AM
Quark Pharmaceuticals Inc. Chief Scientist Provides An Overview Of The Company's Clinical And Nonclinical Pipelines 9/19/2016 9:15:23 AM
Quark Pharmaceuticals Inc. Awarded Key Patent For QPI-1007 Ocular Neuroprotectant 7/29/2016 6:23:12 AM
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016 6:09:02 AM
Quark Pharmaceuticals Inc. To Present Keynote Address At IBC's 18th Annual TIDES Oligonucleotide And Peptide Therapeutics Conference 5/9/2016 9:12:46 AM
Transplant Genomics And Quark Pharmaceuticals Inc. Announce Discovery And Development Collaboration 4/14/2016 6:25:07 AM
Quark Pharmaceuticals Inc. Doses First Patients In Two Pivotal Phase III Studies And One Phase II Study Of RNAi-Based Therapeutics For Kidney And Eye Indications 3/14/2016 6:18:57 AM
Quark Pharmaceuticals Inc. Announces Initiation Of Patient Recruitment For Global Pivotal Study Of QPI-1007 In NAION 10/27/2015 7:40:51 AM
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014 6:31:05 AM